April Issue of All Access Available Now
Precision’s All Access is our bimonthly newsletter with original content written by our payer experts for market access leaders.
In this issue, we cover:
- Real-World Evidence and Value Generation
- The Bipartisan Budget Act of 2018
- The Evolution of Medical Benefit Management Strategies
- Sneak Preview from Precision’s Digital and Data Trends Report
To read our latest edition, click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.